Director of the Board
Milan Zdravkovic (Danish, born 1970) joined PILA PHARMA in June 2022 as Director of the Board due to his significant medical expertise in developing novel diabetes treatments.
Milan Zdravkovic holds an MD (1996) and Ph.D. (2000) from the University of Aarhus, Denmark, and an MSc in Pharmaceutical Medicine from the University of Surrey, UK (2007). In addition, he has received management training at INSEAD (2013) and Harvard Business School (2014).
Milan Zdravkovic has over 25 years of life-science experience including senior RD positions that has led to the approval of novel therapies within diabetes, growth hormone disorders, obesity and immunology.
Notably, he has served as Corporate Project Vice President (CPVP) and Head of the Glucagon Like Peptide-1
(GLP-1) Therapeutic Area at Novo Nordisk A/S, Denmark (2008-2010) which included the development and approval of one of the most successful product categories at Novo Nordisk (GLP-1/Victoza®) as well as building the GLP-1 portfolio.
Other leading roles have been Corporate Project Vice President (CPVP) and Head of the Inflammation and Growth Hormone Therapeutic Area (2010-2013) at Novo Nordisk A/S, Copenhagen, Denmark (2010) / Princeton, NJ, US (2011-2013), Corporate Project Vice President (CPVP) and Head of the Insulin, Growth Hormone and Devices Therapeutic Area at Novo Nordisk A/S, Copenhagen, Denmark (2014-2016) and Chief Medical Officer, Senior Vice President, Head of RD at Swedish Orphan Biovitrum AB (2016-2020) that included experience from rare and orphan diseases, and from a company listed in Sweden.
Currently, Milan Zdravkovic is Chief Medical Officer and Head of RD at SNIPR Biome, Denmark (2020-date). SNIPR Biome is developing CRISPR based medicines and has a pipeline within immunology, oncology, with partnerships in antimicrobial-resistance and cardio-metabolism.
In addition, Milan Zdravkovic has served as Board member in Abarceo AB (2021-2022) and is currently Board member in Empros Pharma AB, Sweden (2020-date).
Finally Milan is author and co-author of more than 50 original publications hereof two publications with > 1000 citations and ten with > 100 citations.